home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Antisense Smo Under The Control Of The PTCH1 Promoter Delivered By An Adenoviral Vector Inhibits The Growth Of Human Pancreatic Cancer

  November, 9 2006 8:39
your information resource in human molecular genetics
In this study, reported in Gene Therapy (Vol. 13, pp. 1587–1594, 2006), and published online on 06 July 2006, the authors (Gao et al.) developed a cell-specific cytotoxic model for the treatment of human pancreatic cancer (HPC) in which expression of antisense Smo (SAS) was under the control of the PTCH1 promoter (ptch/p) delivered by an adenoviral vector (Ad-ptch/p-SAS). Their study suggests that targeting at the Hh signaling pathway may be an effective novel gene therapeutic strategy alone or in combination with other agents for the treatment of pancreatic cancer.


Professor Z Li, Department of Gastroenterology, Changhai Hospital, Second Military Medical University, 174 Chang-Hai Road, Shanghai 200433, China.
E-mail: lizhaoshen111@yahoo.com.cn

Abstract available online.

(C) Gene Therapy.

Posted by: Tressie Dalaya

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.